根据交易所数据,莫德纳(MRNA)股票今日盘中大涨9.28%,引起了市场的广泛关注。这一涨幅较为突出,或许与该公司的发展前景有关。
莫德纳是一家商业阶段的生物技术公司,旗下拥有多个疫苗和治疗药物项目。该公司的新冠疫苗已在2020年获批上市,是首批获批的mRNA疫苗之一。截至目前,莫德纳已有40个mRNA开发项目处于临床试验阶段,涵盖了传染病、肿瘤学、心血管疾病和罗天疫苗和其他mRNA技术平台广受市场关注和看好。
此外,基于公开财报数据,多家投资机构给予了莫德纳股票买入或持有评级。可见莫德纳公司的基本面和长期发展前景获得了资本市场的认可,这或许也是导致该股暴涨的原因之一。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.